Drug intelligence / Profile preview

xinnaoshutong

Development stage: Unknown
Lead developer: Jilin Aodong Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

Xinnaoshutong is a Chinese patent medicine primarily composed of total saponins extracted from the fruit of *Tribulus terrestris* L. It is widely used in China for the treatment of cardiovascular and cerebrovascular diseases, including coronary heart disease, angina pectoris, and ischemic stroke. The drug is thought to exert its therapeutic effects by inhibiting platelet aggregation, improving blood rheology, and protecting vascular endothelial cells. It is often studied in the context of post-stroke recovery and the management of atherosclerosis.

Brand names: Xinnaoshutong心脑舒通
Other names: Xinnaoshutong capsule心脑舒通胶囊Tribulus terrestris saponins

Beyond the preview

Go deeper on xinnaoshutong.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xinnaoshutong.

Explore the full profile